Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2026-06-01 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Fresenius SE & Co. KGaA: Michael Sen, buy
Director's Dealing Classification · 92% confidence The document is a notification of transactions by persons discharging managerial responsibilities (an insider), detailing share acquisitions by a board member (Michael Sen) in Fresenius SE & Co. KGaA. This fits the definition of Director’s Dealing (insider share transactions by directors).
2026-06-01 English
2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a corporate news release reporting the voting outcomes of the 2026 Annual General Meeting, including approval percentages for various agenda items and dividend decisions. It does not present the AGM materials themselves, proxy statements, or the full annual report, but specifically declares vote results, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-23 English
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
AGM Information Classification · 85% confidence The document is a corporate press release summarizing the 2026 Annual General Meeting of Fresenius SE & Co. KGaA, highlighting performance, proposed dividend and linking to the AGM speeches. It is not the full annual report or an earnings release, nor does it report vote results. This aligns with “AGM Information” covering materials and presentations shared at the AGM.
2026-05-22 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a formal notification under Article 40 Section 1 of Germany’s Securities Trading Act (WpHG) detailing the acquisition/disposal of shares and voting rights by The Capital Group Companies, Inc. It specifies the date a threshold was crossed, percentages before and after, and chain of controlled undertakings. There is no reference to AGM vote results; rather, it reports a change in significant shareholding. This matches the ‘Major Shareholding Notification’ category (MRQ).
2026-05-15 English
Fresenius SE & Co. KGaA: Michael Sen, buy
Director's Dealing Classification · 100% confidence The document is a notification of transactions by a person discharging managerial responsibilities (Michael Sen) involving the acquisition of shares in Fresenius SE & Co. KGaA. It details the nature of the transaction, prices, volumes, and dates. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives. The document is not a full financial report, earnings release, or any other type of filing. Therefore, the correct classification is DIRS.
2026-05-08 English
Fresenius invests in Avelios Medical and further expands its strategic partnership with SAP
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Fresenius's investment in Avelios Medical and the expansion of its strategic partnership with SAP. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed report content. The document is a corporate news announcement about a strategic investment and partnership, typical of a Capital/Financing Update. The length is about 6916 characters, which is sufficient for a detailed announcement but does not contain financial report data. Therefore, the best fitting category is Capital/Financing Update (CAP).
2026-05-06 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.